An Ontology for Description of Drug Discovery Investigations

More Information | Back to archive
Full Text of this article Full article [PDF] (946,03 kB)
doi doi:10.2390/biecoll-jib-2010-126
submission February 20, 2010
published March 25, 2010
NCBI PubMed PubMed ID 20375446

Da Qi, Ross D King, Andrew L Hopkins, G Richard J Bickerton and Larisa N Soldatova

Correspondence should be addressed to:
Larisa N Soldatova
Department of Computer Science, Aberystwyth University Wales, United Kingdom, SY23 3DB
ku.ca.reba@nullssl


Abstract

The paper presents an ontology for the description of Drug Discovery Investigation (DDI). This has been developed through the use of a Robot Scientist “Eve”, and in consultation with industry. DDI aims to define the principle entities and the relations in the research and development phase of the drug discovery pipeline. DDI is highly transferable and extendable due to its adherence to accepted standards, and compliance with existing ontology resources. This enables DDI to be integrated with such related ontologies as the Vaccine Ontology, the Advancing Clinico-Genomic Trials on Cancer Master Ontology, etc. DDI is available at http://purl.org/ddi/wikipedia or http://purl.org/ddi/home .

Reference

Da Qi, Ross D King, Andrew L Hopkins, G Richard J Bickerton and Larisa N Soldatova. An Ontology for Description of Drug Discovery Investigations. Journal of Integrative Bioinformatics, 7(3):126, 2010. Online Journal: http://journal.imbio.de/index.php?paper_id=126
imprint | sitemap | credits | top